Lercanidipina Zentiva (Lercanidipine Hydrochloride)

Lercanidipine Hydrochloride, the active ingredient in Lercanidipina Zentiva, is a calcium channel blocker presented as an oral tablet for oral use. It works by relaxing vascular smooth muscle, thereby lowering elevated blood pressure in adult patients with hypertension. The formulation is manufactured under EU standards and is intended for prescription use.

GNH USA supplies Lercanidipina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global healthcare providers.

Lercanidipine is a calcium channel blocker indicated for the management of hypertension.

Hypertension: lowers systolic and diastolic blood pressure in patients with high blood pressure.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache. - Flushing: sensation of warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Angioedema: swelling of face, lips, tongue or throat. - Hepatic dysfunction: elevated liver enzymes or jaundice.

When prescribing lercanidipine, clinicians should consider several precautionary measures to ensure safe use.

- Blood pressure monitoring: check baseline and periodic readings to assess efficacy. - Hepatic impairment: use with caution in patients with liver disease; dose adjustment may be needed. - Elderly patients: start at low dose and monitor for excessive hypotension. - Concomitant antihypertensives: avoid rapid addition of other blood‑pressure‑lowering agents to prevent additive hypotension. - CYP3A4 inhibitors: avoid strong inhibitors (e.g., ketoconazole) or adjust therapy accordingly. - Store at below 25°C: keep tablets in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, affecting its plasma levels or enhancing blood‑pressure effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lercanidipine concentrations and risk of hypotension. - Concomitant use with other potent vasodilators (e.g., nitroglycerin): can cause severe drops in blood pressure. - Grapefruit juice (in large amounts): markedly raises drug exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels. - Diuretics: combined effect may enhance hypotensive response; monitor electrolytes. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect. - Beta‑blockers: additive effect on heart rate and blood pressure; observe for bradycardia.